EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells

Elias Brauneck, Leon-Gordian Leonhardt, Anne Marie Assemissen, Yagana Wahid, Moritz Kruppa, Niklas Kruppa, Julius Krüger, Stephan Menzel, Friedrich Koch-Nolte, Julian Kylies, Katja Weisel, Carsten Bokemeyer und 4 weitere

Cancer Immunology, Immunotherapy · 24.04.2025 · 74 (6)

DOI: 10.1007/s00262-025-04030-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 24.04.2025. Verfasst von Elias Brauneck und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Receptors, Immunologic, Bone Neoplasms, Apyrase, 5'-Nucleotidase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Spine Foundation, Hamburger Krebshilfe, Mildred Scheel Nachwuchszentrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bone metastases (BM) represent one of the most common sites of metastasis. The study aimed to compare the composition of immune cell infiltration from aspirates of different BM prior to systemic therapy.

Method

Phenotypic and functional analyses were conducted via multiparametric flow cytometry (MFC) on BM-derived aspirates obtained from patients with breast cancer (BC, n = 6), patients with prostate cancer (PC, n = 5), patients with non-small-cell lung cancer (NSCLC) ( n = 7), patients with myeloma (MM, n = 10) and bone aspirates from age-matched non-malignant controls (NMC, n = 10).

Results

Across all tumors aspirates the fraction of CD8 + T cells was reduced. In contrast, infiltration by immunosuppressive CD56 + CD16 − NK and CD163 + CD86 + M2-like macrophages was increased in BM compared to NMC aspirates. BM-derived CD8 + T cells aberrantly co-expressed TIGIT with PVRIG or CD39. Similarly, BM-derived cytotoxic NK cells co-expressed TIGIT and PVRIG. In addition, BM-derived M2-like macrophages exhibited an increased subset of cells co-expressing either TIGIT and PVRL4 or CD112 and CD155. Using a myeloma model, functional in vitro studies showed that blockade of TIGIT and CD39 leads to increased PBMC-mediated lysis of myeloma cells.

Conclusion

The study shows that an altered immune cell composition is present in BM across the different tumor entities. Additionally, molecules of the TIGIT checkpoint as well as of the purinergic pathway are aberrantly expressed by BM-infiltrating CD8 + T cells, NK cells and macrophages and also functionally relevant for tumor cell lysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicBone NeoplasmsApyrase5'-NucleotidaseAntigens, CDHumansMaleFemaleKiller Cells, NaturalCD8-Positive T-LymphocytesGPI-Linked ProteinsMiddle AgedMultiple MyelomaAgedMacrophagesBreast Neoplasms

Stichwörter der Autor:innen

Anti-tumor immunityBone metastasisCheckpoint moleculesImmune cellsPurinergic signalingTIGIT axis

Substanzen

Receptors, ImmunologicApyrase5'-NucleotidaseAntigens, CDTIGIT protein, humanNT5E protein, humanGPI-Linked ProteinsCD39 antigen

Autor:innen und Institutionen

  • Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Core Facility Nanobodies, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. f.brauneck@uke.de.

Förderung

  • German Spine Foundation
  • Hamburger Krebshilfe
  • Mildred Scheel Nachwuchszentrum
  • Universitätsklinikum Hamburg-Eppendorf (UKE)

Zitieren

APA

Brauneck, E., Leonhardt, L. G., Assemissen, A. M., Wahid, Y., Kruppa, M., Kruppa, N., Krüger, J., Menzel, S., Koch-Nolte, F., Kylies, J., Weisel, K., Bokemeyer, C., Wellbrock, J., Fiedler, W., Viezens, L., & Brauneck, F. (2025). Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells. Cancer Immunology, Immunotherapy, 74(6). https://doi.org/10.1007/s00262-025-04030-2

Vancouver

Brauneck E, Leonhardt LG, Assemissen AM, Wahid Y, Kruppa M, Kruppa N, et al. Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells. Cancer Immunology, Immunotherapy. 2025;74(6). doi:10.1007/s00262-025-04030-2

BibTeX
@article{Brauneck2025,
  author = {Brauneck, Elias and Leonhardt, Leon-Gordian and Assemissen, Anne Marie and Wahid, Yagana and Kruppa, Moritz and Kruppa, Niklas and Krüger, Julius and Menzel, Stephan and Koch-Nolte, Friedrich and Kylies, Julian and Weisel, Katja and Bokemeyer, Carsten and Wellbrock, Jasmin and Fiedler, Walter and Viezens, Lennart and Brauneck, Franziska},
  title = {Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {6},
  doi = {10.1007/s00262-025-04030-2}
}
Kostenlos starten →